metricas
covid
Revista Colombiana de Reumatología (English Edition) Tofacitinib, an oral Janus kinase inhibitor, in patients from Colombia with rheu...
Journal Information

Statistics

Follow this link to access the full text of the article

Original Investigation
Tofacitinib, an oral Janus kinase inhibitor, in patients from Colombia with rheumatoid arthritis: Pooled efficacy and safety analyses of data from phase III studies
Tofacitinib, un inhibidor oral de la janus kinasa, en pacientes colombianos con artritis reumatoide: análisis de eficacia y seguridad de los estudios de fase III
Patricia Véleza, Juan J. Jallerb, William J. Otero Escalantec, Erika G. Garcíad,1, Ricardo Rojoe, Douglass Chapmanf, Katherine Persandg,1, Giovanna A. Matizg,
Corresponding author
a Reumatología, CIREI SAS, Bogotá, Colombia
b Centro de Reumatología y Ortopedia, Barranquilla, Colombia
c Departamento de Medicina Interna, Facultad de Salud, Universidad Industrial de Santander, Centro de Investigación Clínica Servimed E.U., Bucaramanga, Colombia
d Pfizer Inc, Collegeville, PA, USA
e Pfizer Inc, Groton, CT, USA
f Pfizer Inc, New York, NY, USA
g Pfizer Colombia, Bogotá, Colombia
Read
3081
Times
was read the article
726
Total PDF
2355
Total HTML
Share statistics
Article information
ISSN: 24444405
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 12 19 23 42
2025 11 55 114 169
2025 10 44 47 91
2025 9 35 51 86
2025 8 38 20 58
2025 7 53 10 63
2025 6 57 11 68
2025 5 41 3 44
2025 4 48 2 50
2025 3 41 6 47
2025 2 43 4 47
2025 1 50 1 51
2024 12 24 7 31
2024 11 44 2 46
2024 10 48 11 59
2024 9 51 5 56
2024 8 45 4 49
2024 7 35 4 39
2024 6 40 3 43
2024 5 34 2 36
2024 4 31 5 36
2024 3 46 7 53
2024 2 53 2 55
2024 1 28 1 29
2023 12 47 3 50
2023 11 17 1 18
2023 10 19 2 21
2023 9 11 3 14
2023 8 11 3 14
2023 7 16 2 18
2023 6 22 3 25
2023 5 41 5 46
2023 4 64 6 70
2023 3 46 2 48
2023 2 25 4 29
2023 1 23 11 34
2022 12 13 3 16
2022 11 36 8 44
2022 10 32 8 40
2022 9 15 7 22
2022 8 21 10 31
2022 7 20 6 26
2022 6 27 7 34
2022 5 26 8 34
2022 4 31 10 41
2022 3 17 10 27
2022 2 25 3 28
2022 1 14 3 17
2021 12 13 9 22
2021 11 15 8 23
2021 10 48 9 57
2021 9 29 13 42
2021 8 37 13 50
2021 7 24 11 35
2021 6 28 8 36
2021 5 28 8 36
2021 4 81 34 115
2021 3 55 8 63
2021 2 27 7 34
2021 1 29 14 43
2020 12 28 3 31
2020 11 17 4 21
2020 10 14 3 17
2020 9 21 6 27
2020 8 29 8 37
2020 7 13 8 21
2020 6 22 11 33
2020 5 17 4 21
2020 4 16 2 18
2020 3 12 0 12
2020 2 18 5 23
2020 1 9 2 11
2019 12 17 3 20
2019 11 9 3 12
2019 10 12 7 19
2019 9 12 2 14
2019 8 8 4 12
2019 7 13 17 30
2019 6 20 14 34
2019 5 12 5 17
Show all

Follow this link to access the full text of the article